Anastrozole and MK-2866 Interaction

Avoid
Mechanism-based 64% confidence

Anastrozole and MK-2866 have a potentially harmful interaction with 64% confidence. Both Anastrozole and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the gonads and liver and heart, so monitoring these systems is recommended.

Compound Profiles

Anastrozole

Aromatase Inhibitor | Estrogen Management

Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain.

Half-life: ~40-50 hours Typical dose: 0.25-0.5mg EOD or E3D (estrogen management) pct, anabolic
aromatase androgenicaromatase inhibitorestrogenichepatotoxic
View full profile

MK-2866

Selective Androgen Receptor Modulator | Muscle Wasting Research

MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.

Half-life: ~24 hours Typical dose: 10-25 mg/day oral sarm, anabolic
androgen receptormtormyostatin androgeniccarcinogenic riskhepatotoxichpta suppressive
View full profile

Combined Organ Load

Gonads
elevated
Liver
elevated
Heart
moderate
Pituitary
low

Shared Safety Flags

2x 2 androgenic compounds (Anastrozole, MK-2866). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 hepatotoxic compounds (Anastrozole, MK-2866). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 HPTA-suppressive compounds (Anastrozole, MK-2866). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (Anastrozole, MK-2866). Get lipid panel mid-cycle — consider adding lipid support.

Frequently Asked Questions

Can I take Anastrozole with MK-2866?

Combining Anastrozole with MK-2866 is not recommended. Both Anastrozole and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Anastrozole and MK-2866 safe together?

This combination carries significant risk. Both Anastrozole and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Anastrozole and MK-2866?

Both Anastrozole and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Anastrozole and MK-2866?

Anastrozole has a half-life of ~40-50 hours and MK-2866 has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Anastrozole vs MK-2866

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.